A Double-Blind, Placebo-Controlled, Single Ascending Dose Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse

Trial Profile

A Double-Blind, Placebo-Controlled, Single Ascending Dose Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs RHIgM22 (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Acorda Therapeutics
  • Most Recent Events

    • 29 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 11 May 2017 Planned End Date changed from 1 Aug 2017 to 1 Nov 2017.
    • 11 May 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top